Affluent Medical
Carvolix : Results of the votes of the Combined Shareholders’ General Meeting of January 30, 2026
02-Feb-2026 / 07:30 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Results of the votes of the Combined Shareholders’ General Meeting of January 30, 2026 Aix-en-Provence, February 2, 2026 – 7:30 a.m. CET – Carvolix (formerly Affluent Medical) (ISIN: FR0013333077 – Ticker: AFME – “Carvolix” or the “Company”), a French commercial and clinical-stage medical technology company specializing in the international development and industrialization of breakthrough AI-driven mini-robots and biomimetic implants, to revolutionize interventional cardiology and the treatment of brain stroke, is today announcing the results of the votes of its Combined Shareholders’ Meeting. The Combined Shareholders' Meeting was held on Friday January 30, 2026, at 11 a.m. at the registered office of the Company located 320 avenue Archimède - Les Pleiades III Batiment B -13100 AIX-EN-PROVENCE (France), under the chairmanship of Mr. Michel Thérin, Chairman of the Board of Directors (the “Board”). The shareholders have adopted the resolution regarding the change of Company’s name as well as all the resolutions supported by the Board, and particularly the delegations granted to the Board related to financial transactions. The shareholders have also ratified the appointment of Mr. Alain Chevallier as a Board member, and approved the agreements and commitments referred to in Articles L.225-38 and seq. of the Commercial Code. Details of the vote results are detailed below : Number of shares with voting rights | 39 350 192 | Total number of votes | 57 009 926 | Number of shareholders present, represented or voting by post | 33 | Number of shares present, represented or voting by post | 35 446 196 | Number of votes present, represented or voting by post | 52 614 168 | Participation rate | 92.3 % |
Extraordinary General Shareholders’ Meeting | For | Against | Abstain | Votes | % | Votes | % | Votes | % | -
| Change of the Company's name; | 51 756 208 | 98.37% | 857 960 | 1.63% | 0 | - | -
| Delegation of powers to the Board of Directors to decide, subject to a condition precedent, on a cash capital increase with the removal of preferential subscription rights in favor of named persons, in one or more instalments, for a maximum nominal amount of €1,238,447.00; | 52 614 168 | 100.00% | 0 | 0.00% | 0 | - | -
| Removal of preferential subscription rights in favor of Truffle BioMedTech Crossover; | 45 655 421 | 100.00% | 0 | 0.00% | 6 958 747 | - | -
| Removal of preferential subscription rights in favor of Truffle Innov FRR; | 51 015 787 | 100.00% | 0 | 0.00% | 1 598 381 | - | -
| Removal of preferential subscription rights in favor of Truffle Medeor; | 42 317 293 | 100.00% | 0 | 0.00% | 10 296 875 | - | -
| Delegation of powers to the Board of Directors to decide, subject to a condition precedent, on a cash capital increase with removal of preferential subscription rights in favor of named persons, on one or more instalments, for a maximum nominal amount of €1,428,398.50; | 52 614 167 | 100.00% | 0 | 0.00% | 1 | - | -
| Removal of preferential subscription rights in favor of Truffle BioMedTech Crossover; | 45 655 421 | 100.00% | 0 | 0.00% | 6 958 747 | - | -
| Removal of preferential subscription rights in favor of Truffle Innov FRR; | 51 015 787 | 100.00% | 0 | 0.00% | 1 598 381 | - | -
| Removal of preferential subscription rights in favor of Truffle Medeor; | 42 317 293 | 100.00% | 0 | 0.00% | 10 296 875 | - | -
| Delegation of authority to the Board of Directors to decide, subject to a condition precedent, on a cash capital increase, in one or more instalments, for a maximum nominal amount of €310,730.50; | 52 614 167 | 100.00% | 0 | 0.00% | 1 | - | -
| Removal of preferential subscription rights in favor of Truffle Medeor; | 42 317 293 | 100.00% | 0 | 0.00% | 10 296 875 | - | -
| Removal of preferential subscription rights in favor of Financière Memnon; | 48 867 927 | 100.00% | 0 | 0.00% | 3 746 241 | - | -
| Cancellation of preferential subscription rights in favor of HAYK Holding Sàrl; | 52 414 167 | 100.00% | 0 | 0.00% | 200 001 | - | -
| Removal of preferential subscription rights in favor of Ginko Invest; | 51 568 230 | 100.00% | 0 | 0.00% | 1 045 938 | - | -
| Removal of preferential subscription rights in favor of Ms. Simone Merkle; | 51 756 207 | 100.00% | 0 | 0.00% | 857 961 | - | -
| Delegation of powers to the Board of Directors to decide, subject to a condition precedent, on a cash capital increase with removal of preferential subscription rights in favor of named persons, in one or more instalments, for a maximum nominal amount of €427,350.30; | 52 614 168 | 100.00% | 0 | 0.00% | 0 | - | -
| Removal of preferential subscription rights in favor of Truffle BioMedTech Crossover; | 45 655 421 | 100.00% | 0 | 0.00% | 6 958 747 | - | -
| Removal of preferential subscription rights in favor of Truffle Medeor; | 42 317 293 | 100.00% | 0 | 0.00% | 10 296 875 | - | -
| Removal of preferential subscription rights in favor of Edwards Lifesciences Holding, Inc.; | 48 867 927 | 100.00% | 0 |
|
